1. Home
  2. BNTC vs PFX Comparison

BNTC vs PFX Comparison

Compare BNTC & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • PFX
  • Stock Information
  • Founded
  • BNTC 1995
  • PFX 2010
  • Country
  • BNTC United States
  • PFX United States
  • Employees
  • BNTC N/A
  • PFX N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • PFX Finance: Consumer Services
  • Sector
  • BNTC Health Care
  • PFX Finance
  • Exchange
  • BNTC Nasdaq
  • PFX Nasdaq
  • Market Cap
  • BNTC 88.1M
  • PFX 94.7M
  • IPO Year
  • BNTC N/A
  • PFX N/A
  • Fundamental
  • Price
  • BNTC $9.02
  • PFX $47.45
  • Analyst Decision
  • BNTC Buy
  • PFX
  • Analyst Count
  • BNTC 3
  • PFX 0
  • Target Price
  • BNTC $19.67
  • PFX N/A
  • AVG Volume (30 Days)
  • BNTC 14.6K
  • PFX 501.0
  • Earning Date
  • BNTC 09-19-2024
  • PFX 08-06-2024
  • Dividend Yield
  • BNTC N/A
  • PFX N/A
  • EPS Growth
  • BNTC N/A
  • PFX 36.92
  • EPS
  • BNTC N/A
  • PFX 9.66
  • Revenue
  • BNTC $7,000.00
  • PFX $22,293,269.00
  • Revenue This Year
  • BNTC N/A
  • PFX $19.50
  • Revenue Next Year
  • BNTC N/A
  • PFX $9.74
  • P/E Ratio
  • BNTC N/A
  • PFX $4.91
  • Revenue Growth
  • BNTC N/A
  • PFX 14.03
  • 52 Week Low
  • BNTC $2.69
  • PFX $36.38
  • 52 Week High
  • BNTC $10.88
  • PFX $48.00
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 51.72
  • PFX 57.17
  • Support Level
  • BNTC $8.60
  • PFX $46.87
  • Resistance Level
  • BNTC $9.06
  • PFX $47.00
  • Average True Range (ATR)
  • BNTC 0.40
  • PFX 0.06
  • MACD
  • BNTC -0.02
  • PFX 0.00
  • Stochastic Oscillator
  • BNTC 56.96
  • PFX 97.70

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

About PFX PhenixFIN Corporation

PhenixFIN Corp formerly Medley Capital Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: